Hepatotoxicity is a major concern for the clinical application of novel cancer therapeutics and special care should be taken in the development of therapies containing TNF superfamily members.3 We therefore next assessed the effect of TRAIL and/or SNS-032 treatment on primary human hepatocytes (PHH). The gene discussed is TNF; the disease is cancer.